Schall Law Firm Opens Class Action Against Vistagen Over PALISADE-2 Trial Disclosures
Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.
VTGNsecurities fraudclass action lawsuit
